Kalvista Pharmaceuticals Inc
NASDAQ:KALV

Watchlist Manager
Kalvista Pharmaceuticals Inc Logo
Kalvista Pharmaceuticals Inc
NASDAQ:KALV
Watchlist
Price: 15.52 USD -0.89%
Market Cap: 784.5m USD

Kalvista Pharmaceuticals Inc
Net Income (Common)

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Kalvista Pharmaceuticals Inc
Net Income (Common) Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Income (Common) CAGR 3Y CAGR 5Y CAGR 10Y
Kalvista Pharmaceuticals Inc
NASDAQ:KALV
Net Income (Common)
-$109.6m
CAGR 3-Years
-6%
CAGR 5-Years
-24%
CAGR 10-Years
-16%
Abbvie Inc
NYSE:ABBV
Net Income (Common)
$2.3B
CAGR 3-Years
-44%
CAGR 5-Years
-20%
CAGR 10-Years
-2%
Gilead Sciences Inc
NASDAQ:GILD
Net Income (Common)
$8.1B
CAGR 3-Years
34%
CAGR 5-Years
45%
CAGR 10-Years
-7%
Amgen Inc
NASDAQ:AMGN
Net Income (Common)
$7B
CAGR 3-Years
1%
CAGR 5-Years
-1%
CAGR 10-Years
1%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Net Income (Common)
$3.7B
CAGR 3-Years
4%
CAGR 5-Years
6%
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Net Income (Common)
$4.6B
CAGR 3-Years
-5%
CAGR 5-Years
8%
CAGR 10-Years
23%
No Stocks Found

Kalvista Pharmaceuticals Inc
Glance View

KalVista Pharmaceuticals, Inc. is a clinical stage pharmaceutical company, which engages in the discovery, development, and commercialization of small molecule protease inhibitors. The company is headquartered in Cambridge, Massachusetts and currently employs 70 full-time employees. The company went IPO on 2015-04-09. The firm is focused on the discovery, development and commercialization of small molecule protease inhibitors for diseases with unmet need. The firm has developed a portfolio of small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME). Plasma kallikrein is a serine protease enzyme, which is an early mediator of inflammation and edema. The body modulates the inflammatory effects of plasma kallikrein through a circulating inhibitor protein called C1-esterase inhibitor (C1-INH). The firm is primary focused on the development of the oral plasma kallikrein inhibitors for HAE. The company has two drug program candidates in clinical trials. The Company’s DME program is focused on the development of an intravitreally administered small molecule plasma kallikrein inhibitor, KVD001, which completed a Phase II trial.

KALV Intrinsic Value
11.46 USD
Overvaluation 26%
Intrinsic Value
Price

See Also

What is Kalvista Pharmaceuticals Inc's Net Income (Common)?
Net Income (Common)
-109.6m USD

Based on the financial report for Sep 30, 2025, Kalvista Pharmaceuticals Inc's Net Income (Common) amounts to -109.6m USD.

What is Kalvista Pharmaceuticals Inc's Net Income (Common) growth rate?
Net Income (Common) CAGR 10Y
-16%

Over the last year, the Net Income (Common) growth was 30%. The average annual Net Income (Common) growth rates for Kalvista Pharmaceuticals Inc have been -6% over the past three years , -24% over the past five years , and -16% over the past ten years .

Back to Top